Alcon and Novartis have finally agreed on the terms by which Novartis will buy the Alcon shares it does not already own. The total consideration is valued at $168 per Alcon share, made up of Novartis shares and, if necessary, cash to make up the difference. The exact ratio is ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.